Share on StockTwits

OraSure Technologies (NASDAQ:OSUR) issued its quarterly earnings data on Wednesday. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.08, AnalystRatingsNetwork.com reports. The company had revenue of $26.40 million for the quarter, compared to the consensus estimate of $26.21 million. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. OraSure Technologies updated its Q3 guidance to ($0.05)-($0.04) EPS.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of OraSure Technologies from a “neutral” rating to an “outperform” rating in a research note on Tuesday, June 24th. They now have a $9.20 price target on the stock. On the ratings front, analysts at Jefferies Group reiterated a “buy” rating on shares of OraSure Technologies in a research note on Thursday, June 12th. They now have a $10.00 price target on the stock, up previously from $9.00. Finally, analysts at Raymond James raised their price target on shares of OraSure Technologies from $8.50 to $9.00 in a research note on Thursday, June 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $9.70.

OraSure Technologies (NASDAQ:OSUR) traded up 1.46% on Wednesday, hitting $8.34. The stock had a trading volume of 412,877 shares. OraSure Technologies has a one year low of $4.17 and a one year high of $9.00. The stock has a 50-day moving average of $8.42 and a 200-day moving average of $7.. The company’s market cap is $465.7 million.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.